drugset / Trial / NCT07435584
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)
Phase 1/2
Not yet recruiting
38 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, open-label, multicenter, single-arm Phase Ib/II study evaluating the safety and preliminary efficacy of everolimus in patients with CDK12-deficient refractory metastatic colorectal cancer.
Timeline
- Start
- 2026-03-01
- Primary completion
- 2026-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Everolimus | Small molecule | 7.5 mg | Oral |
| Subject | Everolimus | Small molecule | 10 mg | Oral |